You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Advances in using PARP inhibitors to treat cancer
|
|---|---|
| Published in |
BMC Medicine, March 2012
|
| DOI | 10.1186/1741-7015-10-25 |
| Pubmed ID | |
| Authors |
Shivaani Kummar, Alice Chen, Ralph E Parchment, Robert J Kinders, Jay Ji, Joseph E Tomaszewski, James H Doroshow |
| Abstract |
The poly (ADP-ribose) polymerase (PARP) family of enzymes plays a critical role in the maintenance of DNA integrity as part of the base excision pathway of DNA repair. PARP1 is overexpressed in a variety of cancers, and its expression has been associated with overall prognosis in cancer, especially breast cancer. A series of new therapeutic agents that are potent inhibitors of the PARP1 and PARP2 isoforms have demonstrated important clinical activity in patients with breast or ovarian cancers that are caused by mutations in either the BRCA1 or 2 genes. Results from such studies may define a new therapeutic paradigm, wherein simultaneous loss of the capacity to repair DNA damage may have antitumor activity in itself, as well as enhance the antineoplastic potential of cytotoxic chemotherapeutic agents. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 67% |
| North Macedonia | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 120 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 3% |
| Netherlands | 2 | 2% |
| United Kingdom | 2 | 2% |
| Denmark | 1 | <1% |
| India | 1 | <1% |
| Spain | 1 | <1% |
| Nigeria | 1 | <1% |
| Unknown | 109 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 24 | 20% |
| Researcher | 23 | 19% |
| Student > Bachelor | 17 | 14% |
| Student > Master | 10 | 8% |
| Student > Postgraduate | 6 | 5% |
| Other | 18 | 15% |
| Unknown | 22 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 30 | 25% |
| Medicine and Dentistry | 23 | 19% |
| Biochemistry, Genetics and Molecular Biology | 22 | 18% |
| Chemistry | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 10 | 8% |
| Unknown | 24 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2015.
All research outputs
#14,081,159
of 22,663,969 outputs
Outputs from BMC Medicine
#2,894
of 3,397 outputs
Outputs of similar age
#92,308
of 156,320 outputs
Outputs of similar age from BMC Medicine
#28
of 35 outputs
Altmetric has tracked 22,663,969 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,397 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 43.6. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 156,320 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.